Alvotech (NASDAQ:ALVOW – Get Free Report) is projected to release its results after the market closes on Wednesday, August 19th. Analysts expect the company to announce earnings of ($0.0526) per share and revenue of $103.0040 million for the quarter.
Alvotech Price Performance
NASDAQ:ALVOW opened at $0.15 on Wednesday. Alvotech has a 12 month low of $0.12 and a 12 month high of $3.00. The company has a 50 day simple moving average of $0.20 and a two-hundred day simple moving average of $0.27.
Alvotech Company Profile
Alvotech is a biopharmaceutical company specializing in the development and manufacturing of biosimilar medicines. Headquartered in Reykjavík, Iceland, the company focuses on creating high-quality, cost-effective alternatives to branded biologic therapies. Since its founding in 2013, Alvotech has built an integrated platform that spans research and development, clinical trials, regulatory submissions and commercial manufacturing.
Alvotech’s pipeline includes multiple biosimilar candidates addressing key therapeutic areas such as immunology, oncology and ophthalmology.
See Also
- Five stocks we like better than Alvotech
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
